Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Rises By 47.9%

ABIVAX Société Anonyme (NASDAQ:ABVXGet Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 853,600 shares, a growth of 47.9% from the December 15th total of 577,200 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average trading volume of 162,900 shares, the short-interest ratio is presently 5.2 days.

Analyst Upgrades and Downgrades

ABVX has been the topic of several research reports. JMP Securities restated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $38.67.

Get Our Latest Stock Report on ABIVAX Société Anonyme

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $29,000. BNP Paribas Financial Markets raised its stake in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC boosted its stake in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the last quarter. abrdn plc lifted its stake in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

ABVX opened at $6.29 on Thursday. ABIVAX Société Anonyme has a 1-year low of $5.54 and a 1-year high of $17.02. The company’s fifty day moving average price is $8.22 and its two-hundred day moving average price is $10.33.

About ABIVAX Société Anonyme

(Get Free Report)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

See Also

Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.